Rosic Tea, Naji Leen, Bawor Monica, Dennis Brittany B, Plater Carolyn, Marsh David C, Thabane Lehana, Samaan Zainab
St Joseph's Healthcare.
Michael G DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Neuropsychiatr Dis Treat. 2017 May 24;13:1399-1408. doi: 10.2147/NDT.S129480. eCollection 2017.
There is a significant interindividual variability in treatment outcomes in methadone maintenance treatment (MMT) for opioid use disorder (OUD). This prospective cohort study examines the impact of comorbid psychiatric disorders on continued illicit opioid use in patients receiving MMT for OUD.
Data were collected from 935 patients receiving MMT in outpatient clinics between June 2011 and June 2015. Using linear regression analysis, we evaluated the impact of having a comorbid psychiatric disorder on continued illicit opioid use during MMT, adjusting for important confounders. The main outcome measure was percentage of opioid-positive urine screens for 6 months. We conducted a subgroup analysis to determine the influence of specific comorbid psychiatric disorders, including substance use disorders, on continued illicit opioid use.
Approximately 80% of participants had at least one comorbid psychiatric disorder in addition to OUD, and 42% of participants had a comorbid substance use disorder. There was no significant association between having a psychiatric comorbidity and continuing opioid use (=0.248). Results from subgroup analysis, however, suggest that comorbid tranquilizer (β=20.781, <0.001) and cocaine (β=6.344, =0.031) use disorders are associated with increased rates of continuing opioid use.
Results from our study may serve to guide future MMT guidelines. Specifically, we find that cocaine or tranquilizer use disorder, comorbid with OUD, places patients at high risk for poor MMT outcomes. Treatment centers may choose to gear more intensive therapy toward such populations.
在阿片类物质使用障碍(OUD)的美沙酮维持治疗(MMT)中,个体间治疗结果存在显著差异。这项前瞻性队列研究考察了共病精神障碍对接受MMT治疗OUD患者持续非法使用阿片类物质的影响。
收集了2011年6月至2015年6月期间在门诊接受MMT治疗的935例患者的数据。通过线性回归分析,我们评估了共病精神障碍对MMT期间持续非法使用阿片类物质的影响,并对重要的混杂因素进行了校正。主要结局指标是6个月内阿片类物质尿检呈阳性的百分比。我们进行了亚组分析,以确定特定共病精神障碍(包括物质使用障碍)对持续非法使用阿片类物质的影响。
约80%的参与者除患有OUD外,至少还有一种共病精神障碍,42%的参与者患有共病物质使用障碍。共病精神障碍与持续使用阿片类物质之间无显著关联(P = 0.248)。然而,亚组分析结果表明,共病镇静剂使用障碍(β = 20.781,P < 0.001)和可卡因使用障碍(β = 6.344,P = 0.031)与持续使用阿片类物质的比率增加有关。
我们的研究结果可能有助于指导未来的MMT指南。具体而言,我们发现与OUD共病的可卡因或镇静剂使用障碍会使患者面临MMT治疗效果不佳的高风险。治疗中心可选择针对此类人群开展更强化的治疗。